Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
LGND Stock Chart & Stats
$206.16
-$2.36(-2.14%)
At close: 4:00 PM EST
$206.16
-$2.36(-2.14%)
Day’s Range― - ―
52-Week Range$93.58 - $212.49
Previous CloseN/A
Volume21.09K
Average Volume (3M)210.78K
Market Cap
$4.06B
Enterprise Value$3.44B
Total Cash (Recent Filing)$664.52M
Total Debt (Recent Filing)$451.00M
Price to Earnings (P/E)99.2
Beta1.00
Next Earnings
Mar 04, 2026EPS Estimate
1.54Last Dividend Ex-Date
Jul 02, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)3.09
Shares Outstanding19,681,720
10 Day Avg. Volume232,869
30 Day Avg. Volume210,781
Financial Highlights & Ratios
PEG Ratio4.53
Price to Book (P/B)2.36
Price to Sales (P/S)11.73
P/FCF Ratio20.58
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue13.70
Enterprise Value/Gross Profit15.94
Enterprise Value/Ebitda34.44
Forecast
1Y Price Target
$238.33Price Target Upside15.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)7.54
Revenue Forecast (FY)$263.80M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLigand Pharma reported better-than-expected financial results for their 3Q25, including core revenues and adjusted earnings that surpassed estimates.
Investor ConfidenceInvestors have shown increased interest in Ligand due to its successful earnings, increased financial guidance, and recent deals.
Strategic GrowthThe spin-off of Pelthos Therapeutics resulted in a 13% sales royalty on Zelsuvmi and equity ownership of the new stock.
Bears Say
Ligand Pharma News
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $93.58 and its highest was $212.49 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $4.06B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Mar 04, 2026 which is in 95 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Nov 06, 2025. The company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $1.928 by $1.162.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.54.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,681,720 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $3.09 in its last earnings report, beating expectations of $1.928. Following the earnings report the stock price went up 9.371%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in LGND
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$238.33 (15.60% Upside)
$238.33 (15.60% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.81%
12-Months-Change
Fundamentals
Return on Equity
5.42%
Trailing 12-Months
Asset Growth
54.66%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant growth in core revenue and EPS, an increase in full-year guidance, and successful financial transactions. However, there are some concerns related to increased operating expenses and limited information on the ZELSUVMI launch.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$238.33
▲(15.60% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
2.42% Insiders
42.59% Mutual Funds
28.00% Other Institutional Investors
1.81% Public Companies and
Individual Investors